Flagship Biosciences Acquires Interpace Pharma Solutions from Interpace Biosciences

Interpace Diagnostics Acquires Cancer Genetics' Biopharma Services Business

July 15, 2019

Healthcare Services

Interpace Diagnostics Group, Inc. acquired assets and certain liabilities comprising the Biopharma Services business of Cancer Genetics, Inc. for approximately $23.5 million, with the business continuing to operate from labs in Rutherford, New Jersey and Research Triangle Park, North Carolina. In conjunction with the transaction Ampersand Capital Partners invested $27 million in Interpace via convertible preferred stock to support the acquisition and Interpace’s growth in the clinical diagnostic and biopharma services markets.

1315 Capital and Ampersand Capital Partners Invest $20M in Interpace Biosciences

January 13, 2020

Healthcare Services

Interpace Biosciences entered into an agreement for a $20 million Series B Preferred Stock investment — $19 million from 1315 Capital and $1 million from existing investor Ampersand Capital Partners. The financing (and a coincident one-for-ten reverse stock split) is intended to help Interpace reach cash-flow break-even, accelerate growth and pursue acquisitions; Ampersand also exchanged its Series A preferred for the new Series B shares.

Pace Life Sciences Acquires Biopharma Global

September 8, 2022

Healthcare Services

Pace Life Sciences, a CDMO subsidiary of Pace, has acquired Biopharma Global, a Vienna, Virginia-based regulatory affairs consultancy that specializes in orphan and other high‑unmet‑need drug regulatory support. The acquisition expands Pace's regulatory strategy and submission capabilities for FDA and EMA filings, strengthening its end-to-end development and regulatory services for biotech and pharmaceutical clients.

Arcline Investment Management Acquires Integrated Polymer Solutions (IPS)

July 15, 2019

Manufacturing

Arcline Investment Management acquired Integrated Polymer Solutions (IPS) from Industrial Growth Partners in a transaction that closed on July 12, 2019. IPS, headquartered in Long Beach, California with additional manufacturing in Sheffield, UK, manufactures highly engineered elastomeric components (seals, gaskets, composite tooling) for aerospace, defense, biopharma and specialty industrial end markets.

Integrated Polymer Solutions (Arcline) Acquires Seal Science, Inc.

August 10, 2021

Manufacturing

Integrated Polymer Solutions (IPS), a portfolio company of Arcline Investment Management, has acquired Seal Science, Inc., a designer and manufacturer of engineered elastomeric sealing solutions serving aerospace, naval, medical and industrial markets. The deal is an add-on to IPS's materials science platform intended to expand capability and strengthen IPS's position in critical defense and high‑performance industrial end markets.

Integrated Polymer Solutions Acquires Icon Aerospace Technology

January 7, 2020

Aerospace & Defense

Integrated Polymer Solutions (IPS), a portfolio company of Arcline Investment Management, has acquired Icon Aerospace Technology. The transaction expands IPS' design and manufacturing capabilities in polymer/elastomer aerospace components and adds a third AS9100‑certified facility in Retford, United Kingdom.